Lunai Bioworks Inc. (LNAI) - Total Assets
Based on the latest financial reports, Lunai Bioworks Inc. (LNAI) holds total assets worth $9.86 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lunai Bioworks Inc. - Total Assets Trend (2021–2025)
This chart illustrates how Lunai Bioworks Inc.'s total assets have evolved over time, based on quarterly financial data. Also see LNAI company net worth for the company's overall valuation and market capitalisation.
Lunai Bioworks Inc. - Asset Composition Analysis
Current Asset Composition (June 2025)
Lunai Bioworks Inc.'s total assets of $9.86 Million consist of 12.7% current assets and 87.3% non-current assets. Review Lunai Bioworks Inc. total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $165.99K | 2.0% |
| Goodwill | $5.96 Million | 72.5% |
Asset Composition Trend (2021–2025)
This chart illustrates how Lunai Bioworks Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Lunai Bioworks Inc. share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lunai Bioworks Inc.'s current assets represent 12.7% of total assets in 2025, an increase from 11.0% in 2021.
- Cash Position: Cash and equivalents constituted 1.1% of total assets in 2025, down from 10.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 74.0% of total assets, a decrease from 87.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 72.5% of total assets.
Lunai Bioworks Inc. Competitors by Total Assets
Key competitors of Lunai Bioworks Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Lunai Bioworks Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.19 | 0.13 | 0.17 |
| Quick Ratio | 0.19 | 0.13 | 0.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-15.55 Million | $-25.17 Million | $-11.36 Million |
Lunai Bioworks Inc. - Advanced Valuation Insights
This section examines the relationship between Lunai Bioworks Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.48 |
| Latest Market Cap to Assets Ratio | 1.21 |
| Asset Growth Rate (YoY) | -95.0% |
| Total Assets | $8.23 Million |
| Market Capitalization | $9.93 Million USD |
Valuation Analysis
Above Book Valuation: The market values Lunai Bioworks Inc.'s assets above their book value (1.21x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Lunai Bioworks Inc.'s assets decreased by 95.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lunai Bioworks Inc. (2021–2025)
The table below shows the annual total assets of Lunai Bioworks Inc. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $8.23 Million | -94.95% |
| 2024-06-30 | $163.13 Million | +179.81% |
| 2023-06-30 | $58.30 Million | -31.11% |
| 2022-06-30 | $84.63 Million | -55.36% |
| 2021-06-30 | $189.61 Million | -- |
About Lunai Bioworks Inc.
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; a… Read more